Clinical Trials Logo

GNE Myopathy clinical trials

View clinical trials related to GNE Myopathy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04231266 Active, not recruiting - GNE Myopathy Clinical Trials

Multi-Center Study of ManNAc for GNE Myopathy

MAGiNE
Start date: April 5, 2022
Phase: Phase 2
Study type: Interventional

GNE myopathy is a rare genetic muscle disease characterized by progressive muscle atrophy and weakness. The disease is caused by mutations in the gene that encodes the enzyme that initiates and regulates N-acetylneuraminic acid (Neu5Ac) biosynthesis and glycan sialylation. Currently, there is no therapy available for this disease. N-Acetylmannosamine (ManNAc), an orphan drug in development for GNE myopathy, is an uncharged monosaccharide and the first committed precursor in Neu5Ac biosynthesis. In this randomized, double-blind, placebo-controlled trial the efficacy and long-term safety of ManNAc will be evaluated in subjects with GNE myopathy.